The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events
Open accessAbstract
BACKGROUND: Prolonged lowering of blood pressure after a stroke reduces the risk of recurrent stroke. In addition, inhibition of the renin-angiotensin system in high-risk patients reduces the rate of subsequent cardiovascular events, including stroke. However, the effect of lowering of blood pressure with a renin-angiotensin system inhibitor soon after a stroke has not been clearly established. We evaluated the effects of therapy with an angiotensin-receptor blocker, telmisartan, initiated early after a stroke. METHODS: In a multicenter trial involving 20,332 patients who recently had an ischemic stroke, we randomly assigned 10,146 to receive telmisartan (80 mg daily) and 10,186 to receive placebo. The primary outcome was recurrent stroke. Secondary outcomes were major cardiovascular events (death from cardiovascular causes, recurrent stroke, myocardial infarction, or new or worsening heart failure) and new-onset diabetes. RESULTS: The median interval from stroke to randomization was 15 days. During a mean follow-up of 2.5 years, the mean blood pressure was 3.8/2.0 mm Hg lower in the telmisartan group than in the placebo group. A total of 880 patients (8.7%) in the telmisartan group and 934 patients (9.2%) in the placebo group had a subsequent stroke (hazard ratio in the telmisartan group, 0.95; 95% confidence interval [CI], 0.86 to 1.04; P=0.23). Major cardiovascular events occurred in 1367 patients (13.5%) in the telmisartan group and 1463 patients (14.4%) in the placebo group (hazard ratio, 0.94; 95% CI, 0.87 to 1.01; P=0.11). New-onset diabetes occurred in 1.7% of the telmisartan group and 2.1% of the placebo group (hazard ratio, 0.82; 95% CI, 0.65 to 1.04; P=0.10). CONCLUSIONS: Therapy with telmisartan initiated soon after an ischemic stroke and continued for 2.5 years did not significantly lower the rate of recurrent stroke, major cardiovascular events, or diabetes. (ClinicalTrials.gov number, NCT00153062.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The most compelling support for the prevention of dementia by blood pressure lowering was observed in the Systolic Hypertension Europe (Syst-Eur) trial.442,449”
From Vascular Contributions to Cognitive Impairment and Dementia: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association (2011) · cites this paper as [449]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Dementia was diagnosed in 21 patients from the placebo group and 11 patients from the active treatment group, corresponding to a 50% (95% confidence interval 0% to 76%) decrease in the incidence of dementia in subjects receiving active treatment.”
From Vascular Contributions to Cognitive Impairment and Dementia: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association (2011) · cites this paper as [449]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
Self-citationGlobal mortality, disability, and the contribution of risk factors: Global Burden of Disease Study
Murray, C. J., & Lopez, A. D. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07495-8 · Cited by 4,492
Telmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis
Elliott, W. J., & Meyer, P. M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60108-1 · Cited by 1,016
Blood Pressure and Clinical Outcomes in the International Stroke Trial
Leonardi‐Bee, J., Bath, P. M., Phillips, S. J., & Sandercock, P. A. (2002) · Stroke · doi:10.1161/01.str.0000014509.11540.66 · Cited by 979
Self-citationMorbidity and Mortality After Stroke, Eprosartan Compared With Nitrendipine for Secondary Prevention
Schrader, J., Lüders, S., Kulschewski, A., Hammersen, F., Plate, K., Berger, J., Zidek, W., Dominiak, P., Diener, H., & the MOSES Study Group (2005) · Stroke · doi:10.1161/01.str.0000166048.35740.a9 · Cited by 766
Self-citationEffect of ramipril on the incidence of diabetes
(2006) · New England Journal of Medicine · doi:10.1056/nejmoa065061 · Cited by 737
Cited by
Sorted by citations
Items 301–400 of 785
Renin–angiotensin system blockade: Its contribution and controversy
Miyajima, A., Kosaka, T., Kikuchi, E., & Oya, M. (2015) · International Journal of Urology · doi:10.1111/iju.12827 · Cited by 20
Blood pressure management in stroke patients
Kim, S. M., Woo, H. G., Kim, Y. J., & Kim, B. J. (2020) · Journal of Neurocritical Care · doi:10.18700/jnc.200028 · Cited by 20
Blood Pressure Management After Intracerebral Hemorrhage
Sato, S., Carcel, C., & Anderson, C. S. (2015) · Current Treatment Options in Neurology · doi:10.1007/s11940-015-0382-1 · Cited by 20
Impact of telmisartan on cardiovascular outcome in hypertensive patients at high risk
Foulquier, S., Böhm, M., Schmieder, R. E., Sleight, P., Teo, K. K., Yusuf, S., Schumacher, H., & Unger, T. (2014) · Journal of Hypertension · doi:10.1097/hjh.0000000000000154 · Cited by 20
Self-citationDiabetes, Hypertension, and Outcome Studies: Overview 2010
Nilsson, P. M., & Cederholm, J. (2011) · Diabetes Care · doi:10.2337/dc11-s204 · Cited by 20
Capítulo 9 - Hipertensão Arterial na gestação
Malachias, M. V. B., Souza, W., Plavnik, F. L., Rodrigues, C., Brandão, A., Neves, M. F., Bortolotto, L. A., Franco, R., Poli‐de‐Figueiredo, C. E., Jardim, P., et al. (2016) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20160159 · Cited by 22
Delaitre, C., Boisbrun, M., Lecat, S., & Dupuis, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136738 · Cited by 19
Tablet Formulation of a Polymeric Solid Dispersion Containing Amorphous Alkalinized Telmisartan
Chae, J. S., Chae, B. R., Shin, D. J., Goo, Y. T., Lee, E. S., Yoon, H. Y., Kim, C. H., & Choi, Y. W. (2018) · AAPS PharmSciTech · doi:10.1208/s12249-018-1124-y · Cited by 19
Cerebrovasculoprotective effects of azilsartan medoxomil in diabetes
Abdelsaid, M. A., Coucha, M. M., & Ergul, A. (2014) · Translational research · doi:10.1016/j.trsl.2014.06.003 · Cited by 19
The “J Curve” Problem Revisited: Old and New Findings
Grassi, G. M., Quarti‐Trevano, F., Dell’Oro, R., & Mancia, G. (2010) · Current Hypertension Reports · doi:10.1007/s11906-010-0121-7 · Cited by 16
Takagi, H., & Umemoto, T. (2014) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2014.05.006 · Cited by 18
Preventive pharmacotherapy in type 2 diabetes mellitus
Kalra, S., Choudhary, N., Unnikrishnan, A., & Ajish, T. (2011) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.91183 · Cited by 18
Shih, C.-J., Chen, H., Kuo, S., Li, S., Lai, P.-H., Chen, S., Ou, S., & Chen, Y. (2016) · Canadian Medical Association Journal · doi:10.1503/cmaj.150771 · Cited by 18
Self-citationTargeting blood pressure for stroke prevention: current evidence and unanswered questions
Béjot, Y. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09443-5 · Cited by 18
Cardiovascular Outcomes in High-Risk Patients without Heart Failure Treated with ARBs
khalaf, M. M. A., Thalib, L., & Doi, S. A. R. (2009) · American Journal of Cardiovascular Drugs · doi:10.1007/bf03256593 · Cited by 18
Cao, Z., & Cooper, M. E. (2011) · Acta Diabetologica · doi:10.1007/s00592-011-0328-3 · Cited by 17
An overview of candesartan in clinical practice
Khawaja, Z., & Wilcox, C. S. (2011) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.11.90 · Cited by 19
Blocking the renin–angiotensin system: dual- versus mono-therapy
Ravandi, A., & Teo, K. K. (2009) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.47 · Cited by 18
Zhang, J., Liu, J., Chen, J., Li, X., Wu, Y., Chen, H., Wu, W., Zhang, K., & Gu, L. (2015) · Europe PMC (PubMed Central) · Cited by 17
Blood Pressure Management in Intracerebral Haemorrhage: when, how much, and for how long?
Mutimer, C. A., Yassi, N., & Wu, T. Y. (2024) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-024-01341-2 · Cited by 19
Blood pressure management to prevent recurrent stroke: current evidence and perspectives
Silva, G. S., de Andrade, J. B. C., Martins, E. B., Santo, K., & Machline-Carrion, M. J. (2024) · npj Cardiovascular Health · doi:10.1038/s44325-024-00021-x · Cited by 20
Booysen, H. L., Norton, G. R., Maseko, M. J., Libhaber, C. D., Majane, O. H. I., Sareli, P., & Woodiwiss, A. J. (2013) · Journal of Hypertension · doi:10.1097/hjh.0b013e328360802a · Cited by 17
Volpe, M., & Tocci, G. (2011) · American Journal of Hypertension · doi:10.1038/ajh.2011.105 · Cited by 16
A review of clinical studies on angiotensin II receptor blockers and risk of cancer
Dézsi, C. A. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.11.031 · Cited by 17
Lackland, D. T. (2012) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32835c4f54 · Cited by 20
Regulska, K., Regulski, M., Karolak, B., Michalak, M., Murias, M., & Stanisz, B. J. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104326 · Cited by 17
Telmisartan improves insulin sensitivity: A meta-analysis of randomized head-to-head trials
Takagi, H., & Umemoto, T. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.11.070 · Cited by 17
Wang, Y., Zhang, T., Li, C., Guo, J., Xu, B., & Xue, L. (2021) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13574 · Cited by 17
More indirect evidence of potential neuroprotective benefits of angiotensin receptor blockers
Anderson, C. S. (2010) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283371355 · Cited by 17
Understanding and treating hypertension in diabetic populations.
Volpe, M., Battistoni, A., Savoia, C., & Tocci, G. (2015) · PubMed Central · doi:10.3978/j.issn.2223-3652.2015.06.02 · Cited by 19
Shukla, A. K., Awasthi, K., Usman, K., & Banerjee, M. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i4.606 · Cited by 17
Sandset, E. C., Murray, G. D., Boysen, G., Jatužis, D., Kõrv, J., Lüders, S., Richter, P., Roine, R. O., Terént, A., Thijs, V., et al. (2010) · International Journal of Stroke · doi:10.1111/j.1747-4949.2010.00473.x · Cited by 16
Prospects for Diminishing the Impact of Nonamyloid Small-Vessel Diseases of the Brain
Joutel, A. (2019) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021712 · Cited by 17
Xu, J., Zhao, X., Wang, Y., Wang, C., Liu, L., Sun, B., Wang, A., & Wang, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065233 · Cited by 16
Telmisartan and cardioprotection
McFarlane, S. (2011) · Vascular Health and Risk Management · doi:10.2147/vhrm.s9447 · Cited by 17
Frampton, J. E. (2011) · Drugs · doi:10.2165/11206710-000000000-00000 · Cited by 16
Management of Arterial Blood Pressure in Acute Ischemic and Hemorrhagic Stroke
Hocker, S. E., Morales‐Vidal, S., & Schneck, M. J. (2010) · Neurologic Clinics · doi:10.1016/j.ncl.2010.03.021 · Cited by 16
Li, Y., Chen, J., Lin, T., Wang, Y.-C., Wu, C., Yeh, H., Huang, C., Chang, K., Wu, C., Chen, P., et al. (2019) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2019.04.007 · Cited by 17
Kuwashiro, T., Sugimori, H., Kamouchi, M., Ago, T., Kitazono, T., & Iida, M. (2011) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2010.12.011 · Cited by 16
Zambon, A., Arfè, A., Corrao, G., & Zanchetti, A. (2013) · Journal of Hypertension · doi:10.1097/hjh.0000000000000077 · Cited by 15
Tadic, M. V., Ivanovic, B. A., & Cuspidi, C. (2013) · Blood Pressure · doi:10.3109/08037051.2013.814234 · Cited by 13
Blood pressure lowering and stroke
Saini, M., & Shuaib, A. M. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.162 · Cited by 15
Blood pressure levels and the risk of intracerebral hemorrhage after ischemic stroke
Hilkens, N. A., Greving, J. P., Algra, A., & Klijn, C. J. M. (2016) · Neurology · doi:10.1212/wnl.0000000000003489 · Cited by 16
Disability and Recurrent Stroke Among Participants in Stroke Prevention Trials
de Havenon, A., Viscoli, C. M., Kleindorfer, D., Sucharew, H. J., Delic, A., Becker, C. J., Robinson, D., Yaghi, S. R., Li, V., Lansberg, M. G., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.23677 · Cited by 14
Preston, R. A., Karim, A., Dudkowski, C., Zhao, Z., Garg, D. C., Lenz, O., & Sica, D. A. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0044-y · Cited by 14
Nilsson, P. M. (2011) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b1101001 · Cited by 15
Evidence for the efficacy of ARBs across the cardiovascular continuum
Gupta, M., Honos, G. N., Velazquez, E. J., Chung, N., Oigman, W., & Maggioni, A. P. (2010) · Current Medical Research and Opinion · doi:10.1185/03007991003712159 · Cited by 14
Blood pressure targets for hypertension in patients with type 2 diabetes
Aronow, W. S., & Shamliyan, T. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.04.36 · Cited by 15
Xing-hua, L. I. U., Ma, L., & Li, Z. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01179-8 · Cited by 14
Pharmacotherapy for hypertension-induced left ventricular hypertrophy
Leache, L., Gutiérrez‐Valencia, M., Finizola, R. M., Infante, E., Finizola, B., Pardo, J. P., Flores, Y., Granero, R., & Arai, K. J. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012039.pub3 · Cited by 14
Medical prevention of stroke and stroke recurrence in patients with TIA and minor stroke
Weber, R., Weimar, C., & Diener, H. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903048934 · Cited by 14
Self-citationKeating, G. M. (2009) · Drugs · doi:10.2165/00003495-200969090-00008 · Cited by 14
Update of Cerebral Vascular Disease: Issues for the Primary Care Physician
Gorelick, P. B., & Ruland, S. D. (2010) · Disease-a-Month · doi:10.1016/j.disamonth.2009.12.001 · Cited by 14
Self-citationRundek, T., & Sacco, R. L. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4160-5478-8.10015-6 · Cited by 14
Self-citationStrauss, M. H., & Hall, A. S. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.09.011 · Cited by 16
Dans, A. L., Teo, K. K., Gao, P., Chen, J.-H., Jae-Hyung, K., Yusoff, K., Chaithiraphan, S., Zhu, J., Lisheng, L., Yusuf, S., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013694 · Cited by 14
Self-citationThe corporate bias and the molding of prescription practices: the case of hypertension
Fuchs, F. D. (2009) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2009000300002 · Cited by 14
Cardiovascular Prevention in Clinical Practice (ESC and German Guidelines 2007)
Gohlke, H., Albus, C., Gysan, D. B., Hahmann, H., & Mathes, P. (2009) · Herz · doi:10.1007/s00059-009-3196-7 · Cited by 14
Kintscher, U. (2009) · Journal of Hypertension · doi:10.1097/01.hjh.0000354519.67451.96 · Cited by 14
Sagris, D., Ntaios, G., & Milionis, H. J. (2023) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2022-329149 · Cited by 13
Risk of cancer associated with the use of angiotensin II-receptor blockers
Olin, J. L., Veverka, A., & Nuzum, D. S. (2011) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp100570 · Cited by 13
Medical Management for Secondary Stroke Prevention
Kim, A. S. (2020) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000849 · Cited by 14
Neurological complications of systemic hypertension
Loewenstein, D., & Rabbat, M. (2021) · Handbook of clinical neurology · doi:10.1016/b978-0-12-819814-8.00018-4 · Cited by 11
Tharmaratnam, D., Karayiannis, C., Collyer, T. A., Arima, H., McClure, L. A., Chalmers, J. P., Anderson, C. S., Benavente, O., White, C. L., Algra, A., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.022240 · Cited by 13
Update of secondary stroke prevention
Diener, H., & Weimar, C. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp068 · Cited by 13
Self-citationClinical experiences and case review of angiotensin II receptor blocker‐related angioedema in Korea
Kim, H., Baik, S. Y., Yang, S. J., Kim, T. M., Lee, S., Cho, J., Choi, I. Y., Kim, J. H., Yoon, K., & Kim, H. (2018) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13097 · Cited by 13
Blood pressure targets: are clinical guidelines wrong?
Arguedas, J. A. (2010) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e32833a6dee · Cited by 13
Critical review of cancer risk associated with angiotensin receptor blocker therapy
Waeber, B., Wuerzner, G., & Burnier, M. (2011) · Vascular Health and Risk Management · doi:10.2147/vhrm.s13552 · Cited by 12
Recent Clinical Trials in Atrial Fibrillation in Hypertensive Patients
Manolis, A. J., Kallistratos, M. S., & Poulimenos, L. E. (2012) · Current Hypertension Reports · doi:10.1007/s11906-012-0268-5 · Cited by 12
Catalá-López, F., Hutton, B., & Moher, D. (2014) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2013.11.016 · Cited by 12
Fuchs, F. D. (2012) · BMJ Evidence-Based Medicine · doi:10.1136/eb-2012-100851 · Cited by 12
Volpe, M. (2012) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.12.80 · Cited by 12
Oprisiu, R., Faure, S., Mazouz, H., Boutitie, F., Sérot, J., Achard, J., Godefroy, O., Hanon, O., Temmar, M., Albu, A., et al. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.88 · Cited by 14
Park, S. Y., Jin, C. H., Goo, Y. T., Chae, B. R., Yoon, H. Y., Kim, C. H., Song, S. H., Han, S. B., & Choi, Y. W. (2020) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2020.1834580 · Cited by 12
Harvey, R. L., Roth, E. J., Yu, D., & Celnik, P. A. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0884-4.10050-3 · Cited by 12
New strategies for the prevention of stroke
Liu, A., Guo, J., Xia, W., & Su, D. (2009) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2009.05230.x · Cited by 12
Wang, J., Pimenta, E., & Chwallek, F. (2014) · Vascular Health and Risk Management · doi:10.2147/vhrm.s59429 · Cited by 12
Strauss, M. H., & Hall, A. S. (2009) · Stroke · doi:10.1161/strokeaha.109.559062 · Cited by 12
Leveraging Mendelian randomization to inform drug discovery and development for ischemic stroke
Daghlas, I., & Gill, D. (2024) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x241305916 · Cited by 11
Mao, Y.-C., Ge, S., Qi, S.-F., & Tian, Q. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.986502 · Cited by 13
Fuchs, F. D., & DiNicolantonio, J. J. (2015) · Open Heart · doi:10.1136/openhrt-2014-000236 · Cited by 11
Shih, C.-J., Chu, H., Ou, S., & Chen, Y. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.07.053 · Cited by 11
Bauza, C. E., Martin, R. H., Yeatts, S. D., Borg, K. T., Magwood, G., Selassie, A. W., & Ford, M. E. (2018) · Stroke Research and Treatment · doi:10.1155/2018/4812712 · Cited by 11
Self-citationNotaro, L. A., Usman, M. H., Burke, J. F., Siddiqui, A., Superdock, K. R., & Ezekowitz, M. D. (2009) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2009.00087.x · Cited by 12
Blood Pressure Reduction in Secondary Stroke Prevention
Qureshi, A. I., & Sapkota, B. L. (2011) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000410032.34477.58 · Cited by 11
Wang, Z., Wei, L., Yin, C., Li, W., & Wan, B. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13020243 · Cited by 10
Zeng, W., Wang, T., Stürmer, T., He, N., Shen, P., Lin, H., Guan, X., & Xu, Y. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02753-1 · Cited by 10
Renin–angiotensin–aldosterone system and blood pressure regulation
Seravalle, G., & Grassi, G. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-96120-2.00002-9 · Cited by 10
Pre‐hypertension: how low to go and do drugs have a role?
McInnes, G. T. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04092.x · Cited by 10
Single-Pill Telmisartan and Amlodipine
Suárez, C. (2011) · Drugs · doi:10.2165/11594510-000000000-00000 · Cited by 11
Dalan, R., Jong, M., Choo, R. W. M., Chew, D. E. K., & Leow, M. K. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.08.128 · Cited by 10
New clinical concepts after the ONTARGET trial
Ruilope, L. M., Segura, J., & Zamorano, J. L. (2011) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.11.52 · Cited by 10
Pharmacotherapy for hypertension-induced left ventricular hypertrophy
Finizola, R. M., Infante, E., Finizola, B., Pardo, J. P., Flores, Y., Granero, R., & Arai, K. J. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012039 · Cited by 10
Schrader, J. (2009) · Der Internist · doi:10.1007/s00108-008-2291-9 · Cited by 10
Segura, J., Banegas, J. R., & Ruilope, L. M. (2013) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12126 · Cited by 10
Angiotensin receptor blockers in hypertension. New insights from Japan
Verdecchia, P., Angeli, F., Mazzotta, G., Ambrosio, G., & Reboldi, G. (2010) · Hypertension Research · doi:10.1038/hr.2010.13 · Cited by 10
Capítulo 10 - Hipertensão na Criança e no Adolescente
Malachias, M. V. B., Souza, W., Plavnik, F. L., Rodrigues, C., Brandão, A., Neves, M. F., Bortolotto, L. A., Franco, R., Figueiredo, C., Jardim, P., et al. (2016) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20160160 · Cited by 9
Treating hypertension in type 2 diabetes
Grossman, Y., Shlomai, G., & Grossman, E. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.947267 · Cited by 9
Catalá-López, F., Hutton, B., & Moher, D. (2014) · Revista Española de Cardiología · doi:10.1016/j.recesp.2013.11.016 · Cited by 9
McAlister, F. A., Majumdar, S. R., Padwal, R. S., Fradette, M., Thompson, A., Tsuyuki, R. T., Grover, S. A., Dean, N., & Shuaib, A. M. (2010) · Implementation Science · doi:10.1186/1748-5908-5-27 · Cited by 9
Metadata
- Authors
- Yusuf, S., Diener, H.-C., Sacco, R. L., Cotton, D., Ôunpuu, S., Lawton, W. A., Palesch, Y., Martin, R. H., Albers, G. W., Bath, P., Bornstein, N., Chan, B. P. L., Chen, S.-T., Cunha, L., Dahlöf, B., De Keyser, J., Donnan, G. A., Estol, C., Gorelick, P., Gu, V., Hermansson, K., Hilbrich, L., Kaste, M., Lu, C., Machnig, T., Pais, P., Roberts, R., Skvortsova, V., Teal, P., Toni, D., VanderMaelen, C., Voigt, T., Weber, M., & Yoon, B.-W.
- Affiliations
- Population Health Research Institute (CA)
- University of Duisburg-Essen (DE)
- University of Miami (US)
- Boehringer Ingelheim (United States) (US)
- Medical University of South Carolina (US)
- Stanford Medicine (US)
- University of Nottingham (GB)
- Tel Aviv Sourasky Medical Center (IL)
- National University Hospital (SG)
- Chang Gung Memorial Hospital (TW)
- Sahlgrenska University Hospital (SE)
- The University of Melbourne (AU)
- University of Illinois Chicago (US)
- Helsinki University Hospital (FI)
- St.John's Medical College Hospital (IN)
- McMaster University (CA)
- Pirogov Russian National Research Medical University (RU)
- University of British Columbia (CA)
- Sapienza University of Rome (IT)
- SUNY Downstate Health Sciences University (US)
- Seoul National University Hospital (KR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-09-18
- Volume
- 359
- Issue
- 12
- Pages
- 1225-1237
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC2714258
- OpenAlex
- W2111421663
- Cited by
- 785
- References
- 19
- Citations by year
- 2026: 15 · 2025: 20 · 2024: 23 · 2023: 24 · 2022: 24 · 2021: 21 · 2020: 18 · 2019: 27 · 2018: 34 · 2017: 48 · 2016: 45 · 2015: 41 · 2014: 55 · 2013: 47 · 2012: 70
- FWCI
- 65.49
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- HAL (submittedVersion, other-oa)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion)
- Nottingham ePrints (University of Nottingham) (submittedVersion)
- Repository@Nottingham (University of Nottingham) (submittedVersion, cc-by)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Repository@Nottingham (University of Nottingham) (submittedVersion, other-oa)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi dell Aquila (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Novo Nordisk
- Servier
- National Institutes of Health (5k23ns054084-05)
- Bayer Vital
- National Institute of Neurological Disorders and Stroke (K23-NS054084)
- Daiichi Sankyo Europe
- Cilag
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Keywords
- telmisartan, ischemic stroke, stroke recurrence, renin-angiotensin system blockade, angiotensin receptor blockers, blood pressure reduction, major cardiovascular events, myocardial infarction, heart failure, new-onset diabetes, secondary stroke prevention, cardiovascular mortality, cardiovascular risk reduction
- MeSH terms
- Telmisartan, Aged, Angiotensin-Converting Enzyme Inhibitors, Benzimidazoles, Benzoates, Blood Pressure, Cardiovascular Diseases, Creatinine, Diabetes Mellitus, Female, Follow-Up Studies, Heart Failure, Humans, Male, Middle Aged, Myocardial Infarction, Potassium, Treatment Failure, Stroke, Kaplan-Meier Estimate, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
